Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 YearsDecember 5th 2013
A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.
TRINOVA-1 Trial: Promise for Trebananib in Ovarian CancerDecember 4th 2013
Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.
Additional OS and PFS Benefits With Aflibercept in Post-Hoc VELOUR AnalysisDecember 3rd 2013
A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with mCRC.
Model Emerges for Targeting Oncogenes in NSCLCDecember 3rd 2013
Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.